Skip to content
Medxy AI
  • Wellness & Lifestyle
  • Clinical Updates
  • Medical News
  • Wellness & Lifestyle
  • Clinical Updates
  • Medical News
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • cytarabine
Intermediate-Dose Cytarabine Matches High-Dose Efficacy with Fewer Side Effects in Postinduction AML Therapy
Posted inClinical Updates Wellness & Lifestyle

Intermediate-Dose Cytarabine Matches High-Dose Efficacy with Fewer Side Effects in Postinduction AML Therapy

Posted by By MedXY 08/05/2025
A major RCT shows intermediate-dose cytarabine is noninferior to high-dose as postinduction therapy in AML, with similar survival and lower toxicity.
Read More
  • Silent Damage: Blood Pressure and Subclinical Cardiovascular Injury in Adolescents—Insights from the SHIP AHOY Study
  • Decoding Oncology Trial Endpoints: OS, DFS, PFS, ORR, CR, PR, SD, PD, and DCR Explained
  • Beyond Negative: Quantitative Fecal Hemoglobin Levels Refine Colorectal Cancer Risk Stratification in FIT-based Screening
  • Overcoming PD-1 Inhibitor Resistance: Six Emerging Strategies from the 2025 ASCO Annual Meeting
  • Unveiling Altered Blood Pressure Reflexes in Women with Endometriosis: Implications for Cardiovascular Health
  • About us
  • Contact us
  • Privacy Policy
  • Subscribe Now!
  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease Antibiotics blood pressure breast cancer cancer prevention cardiovascular health cardiovascular risk clinical trial clinical trials Dementia depression diabetes diagnosis diet epidemiology exercise FDA FDA approval health healthcare HIV Hypertension immunotherapy longevity men's health mental health nutrition obesity Pediatrics Pregnancy prevention public health randomized trial semaglutide sexual health sleep stroke targeted therapy treatment type 2 diabetes Vaccine weight loss wellness women's health

Your health, we care

Copyright 2025 — Medxy AI. All rights reserved.
Scroll to Top